Abstract:In a large cohort (n=77), we characterized the molecular, clinicopathological, and prognostic characteristics of H3 K27M‐mutant spinal cord diffuse glioma. ATRX mutation, CDK6 amplification, RB pathway alteration, a higher number of Copy number variant (CNV) events, chromosome (Chr) 9p deletion, and Chr 10p deletion is associated with worse survival. Glioblastoma histological type and a high Ki‐67 index (>10%) are associated with a worse prognosis. Interestingly, the histological type, an independent prognostic factor in multivariate Cox regression, can stratify molecular features of H3 K27M‐mutant spinal cord glioma, including the RB pathway and PI3K pathway. H3 K27‐altered diffuse midline glioma is a highly lethal pediatric‐type tumor without efficacious treatments. Recent findings have highlighted the heterogeneity among diffuse midline gliomas with different locations and ages. Compared to tumors located in the brain stem and thalamus, the molecular and clinicopathological features of H3 K27‐altered spinal cord glioma are still largely elusive, thus hindering the accurate management of patients. Here we aimed to characterize the clinicopathological and molecular features of H3 K27M‐mutant spinal cord glioma in 77 consecutive cases. We found that the H3 K27M‐mutant spinal cord glioma, with a median age of 35 years old, had a significantly better prognosis than H3 K27M‐mutant brain tumors. We noticed a molecular heterogeneity of H3 K27M‐mutant spinal cord astrocytoma via targeted sequencing with 34 cases. TP53 mutation which occurred in 58.8% of cases is mutually exclusive with PPM1D (26%) and NF1 (44%) mutations. The TP53‐mutant cases had a significantly higher number of copy number variants (CNV) and a marginally higher proportion of pediatric patients (age at diagnosis 10%) are associated with a worse prognosis. Interestingly, the histological type, an independent prognostic factor in multivariate Cox regression, can also stratify molecular features of H3 K27M‐mutant spinal cord glioma, including the RB pathway, KRAS/PI3K pathway, and chromosome arms CNV. In conclusion, although all H3 K27M‐mutant spinal cord diffuse glioma were diagnosed as WHO Grade 4, the histological type, molecular features representing chromatin instability, and molecular alterations associated with accelerated cell proliferative activity should not be ignored in clinical management.

Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study

Exploring MRI Characteristics of Brain Diffuse Midline Gliomas with the H3 K27M Mutation Using Radiomics

Biom-43. Somatictp53, Pik3R1, Nf1 Ortert Mutations Are Associated With Inferior Clinical Outcome In H3K27M-Altered Diffuse Midline Glioma: An International, Multi-Institutional Study

Path-40. Clinical Characterization Of H3K27M-Mutant Gliomas

Clinical Features and Prognosis of Diffuse Midline Glioma: A Series of 24 Cases

Diffuse midline glioma with <i>H3</i> K27M mutation in the spinal cord: A series of 33 cases

H3K27M Mutation Doesn't Mean Worse Prognosis in Old Patients

Differences in Survival Prognosticators Between Children and Adults with H3K27M‐mutant Diffuse Midline Glioma

Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children A Retrospective Series of 164 Cases

Clinical and Molecular Characteristics of Thalamic Gliomas: Retrospective Report of 26 Cases

Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?

Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance

Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis

The Biological Behavior of High-Grade Glioma in H3K27M Mutant Circumscribed Midline Gliomas

Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma

[Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].

Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma

Genomic Profiling Identified Novel Prognostic Biomarkers in Chinese Midline Glioma Patients

HGG-33. Prognostic Factors of H3K27M Histone-Mutant Diffuse Midline Gliomas in Patients ≤18Yrs

Clinical features and prognosis of spinal diffuse midline gliomas with H3K27M mutation

A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma